VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 166 filers reported holding VANDA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 6.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,106 | +6.7% | 262 | +9.2% | 0.00% | – |
| Q3 2023 | $1,037 | -9.6% | 240 | +37.9% | 0.00% | – |
| Q2 2023 | $1,147 | -1.8% | 174 | 0.0% | 0.00% | – |
| Q1 2023 | $1,168 | -81.1% | 174 | -79.2% | 0.00% | -100.0% |
| Q4 2022 | $6,171 | -31.4% | 835 | -3.1% | 0.00% | -50.0% |
| Q3 2022 | $9,000 | 0.0% | 862 | +0.6% | 0.00% | +33.3% |
| Q2 2022 | $9,000 | +12.5% | 857 | +14.6% | 0.00% | 0.0% |
| Q1 2022 | $8,000 | -33.3% | 748 | -4.7% | 0.00% | -25.0% |
| Q4 2021 | $12,000 | -7.7% | 785 | +4.5% | 0.00% | -20.0% |
| Q3 2021 | $13,000 | -27.8% | 751 | -10.8% | 0.01% | -28.6% |
| Q2 2021 | $18,000 | 0.0% | 842 | -30.3% | 0.01% | 0.0% |
| Q1 2021 | $18,000 | +38.5% | 1,208 | +13.9% | 0.01% | +40.0% |
| Q4 2020 | $13,000 | +30.0% | 1,061 | +0.7% | 0.01% | +25.0% |
| Q3 2020 | $10,000 | +25.0% | 1,054 | +34.4% | 0.00% | 0.0% |
| Q2 2020 | $8,000 | -11.1% | 784 | -13.5% | 0.00% | -20.0% |
| Q1 2020 | $9,000 | – | 906 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
| Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
| Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
| GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
| Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
| UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
| Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
| Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
| 361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |